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QA of a number of system parameters for a modern proton PBS-dedicated treatment delivery unit. Several authors have published on proton daily QA using either commercial or in-house developed devices. [3] [4] [5] [6] [7] [8] [9] Arjomandy et al. 3 pub- Therapy Center at Houston (PTC-H). Arjomandy et al. 3 verified the output, distal range, and spread-out Bragg Peak (SOBP) for daily QA of DS proton beams using the solid-water plastic. In 2012, Ding et al. 4 initially investigated the use of Sun Nuclear Daily-QA 3 (DQA-3)
device (Sun Nuclear Inc., Melbourne, FL, USA) for daily QA of US proton beams. In 2014, Lambert et al. 5 extended the use of DQA-3
for daily QA of PBS proton beams. For PBS dosimetric tests, Lambert et al. 5 evaluated the output, range, spot sigma, and position.
Since the DQA-3 was originally designed for photon and electron daily QA, authors 4, 5 manufactured an in-house phantom to use with the DQA-3. Actis et al. 6 published on PBS daily QA in 2017 utilizing an in-house developed phantom that can accommodate multi-leaf ionization chamber (MLIC). Actis et al. 6 included beam characteristics (spot width, size, and position), range, and dose output for the dosi- 
| MATERIALS AND METHODS
Our proton center is structured as a multi-vendor hardware and software platform environment. PBS proton plans are generated in RayStation (v.6.1.1.2; RaySearch Laboratories, Stockholm, Sweden), whereas ARIA (v.13.7; Varian Medical Systems, Palo Alto, CA) is used as the department record and verify system. IBA (Ion Beam Applications, Louvain-la-Neuve, Belgium) provides the ProteusPLUS PBS proton therapy system, which includes adaPT-Deliver (v.11.0.3)
for beam delivery and adaPT-Insight (v.2.1.0d) for imaging (kV-kV x ray and kV-CBCT). Additionally, the CatalystPT (C-RAD, Uppsala, Sweden) system is used for surface imaging and gating applications.
The flow chart of data transfer among the various software entities is presented in Fig. 1 .
2.A | Beam delivery system (BDS)
A PBS proton beam is delivered using a PBS dedicated nozzle ( 
2.B | Imaging systems
The kV x-ray imaging system includes two gantry mounted, x-ray tubes that rotate with the gantry. The first x-ray tube (portal) is In addition to the x ray based imaging system, the CatalystPT, a three-camera surface imaging system, is used to setup patients prior to x ray based imaging, monitor patient position and posture during treatment, and enable beam gating. The three cameras are positioned to maximize field coverage with the outer cameras being 43°f rom the center camera.
2.C | Record and verify system
ARIA (v13.7) receives computed tomography (CT) images, DICOM structure set, RT Plan, RT Dose, and DRR images from RayStation.
ARIA also receives the treatment record from adaPT Deliver and images (kV planar/CBCT images) from adaPT Insight.
2.D | Phantoms and detectors
The Sphinx phantom has a carbon frame with dimension of 540 mm × 400 mm × 400 mm ( this rising part of signal is then calculated in order to identify the physical edge of the corresponding RW3 block. 10 The final depthdose curve is calculated by assigning a value of depth to each pixel of the image. 10 The values of depths are extrapolated from data interpolated with a cubic spline fit. 10 For better understanding on the range calculation using wedge, readers are advised to refer to work published by Shen et al. 11 and Deng et al.
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The phantom also has an insert containing a pin with a fiducial at its tip which is placed at the isocenter (Fig. 3) . A dedicated RW3
insert (160 mm × 90 mm × 100 mm) contains a notch for a PPC05 chamber for dose output constancy check. The PPC05 is covered with 3 cm thickness RW3 block so the chamber has a 3 cm build up ( 
2.E | Workflow
Our current daily QA workflow includes two daily QA plans based on two sets of devices: (a) Sphinx, Lynx, and PPC05 and (b) MIMI and HexaCheck.
2.E.1 | Sphinx, Lynx, and PPC05
A daily QA plan was generated in RayStation (v.6.1.1.2) with spot map of four different energies (Fig. 4) . In order to mimic patient treatment, a daily QA plan is delivered using adaPT-Deliver on ProteusPLUS proton therapy system through ARIA. Dosimetry measurements are performed using a single couch top setup with the Sphinx, Lynx, and PPC05 chamber ( and an in-house excel sheet and DOSE 2 electrometer (IBA Dosimetry, Schwarzenbruck, Germany) were used for test #e. Additionally, verification of patient positioning system (PPS) displacement and lasers alignment is accomplished with the same setup. The workflow using Sphinx, Lynx, and PPC05 is presented in Fig. 6 . The total time for this workflow is from 15 to 20 min without system interruptions.
2.E.2 | MIMI and HexaCheck
A treatment plan with kV-kV and CBCT setup fields was generated in RayStation using the CT images of the MIMI phantom. The plan treatment isocenter was defined at the center of the MIMI. The MIMI is placed in the HexaCheck and indexed to the couch top such that MIMI is aligned to the known translational and rotational offset shifts (Fig. 7) Specifically, the known translational shifts were −13.4 mm in the lateral, −9.1 mm in the longitudinal, and 10.8 mm in the vertical directions, whereas the known rotational shifts were 2.2°for the pitch, −2.2°for the roll, and 3.5°for the yaw. First, a CBCT is acquired with
The spot map of a plan created in RayStation for four different proton beam energies (221, 172, 145, and 106 MeV) for the dosimetric testing of the pencil beam scanning daily quality assurance using the Sphinx and Lynx devices is shown.
F I G . 5. The daily couch top setup of the Sphinx, Lynx, and PPC05 for pencil beam scanning dosimetric testing of the daily quality assurance procedure is shown. The gantry is set at 90°with the robotic couch being set to 0°. this workflow is about 10 min.
where, p = translational (e.g., lateral) or rotational parameter (e.g., 
3.A | Dose output and field homogeneity
Dose output and field homogeneity were evaluated for energies of 172 and 221 MeV, respectively. Table 2 and Fig. 10 show that the average Δ in dose output was −0.2% (range, −1.1%-1.5%) relative to baseline, and the Δ in field homogeneity was within ±1% (range, −1.0%-0.7%). The 3σ of the dose output and field homogeneity were ±0.7% and ±0.3%, respectively (Table 2) .
3.B | Energy, width, and DFO
The energy, width, and DFO were evaluated for 106, 145, 172, and 221 MeV energies. Table 2 shows the Δ in distal and proximal ranges (R80) were within ±0.5 mm for all four energies. For both the distal and proximal ranges, the 3σ (Table 2 ) of all four energies was ±0.3 mm. For both the width and DFO, the Δ was within ±0.4 mm.
The 3σ (Table 2 ) of width for all four energies was ±0.2 mm, whereas the 3σ of DFO was ±0.1 mm for energies 145, 172, and 221 MeV and 0 mm for 106 MeV.
3.C | Spots characteristics
Spots characteristics (position, size, and skewness) were evaluated for four spots (106, 145, 172, and 221 MeV). Table 3 and Figs. 11 (Table 3 ). The 3σ of spot skewness ranged from ±0.2 to ±0.3 (Table 3 ).
Test items

Safety
3.D | X-ray vs proton beam coincidence Table 2 and Fig. 13 show that the Δ in x-ray and proton beam coincidence (X and Y directions) was within ±1 mm except in one case (Δ = 1.3 mm). The 3σ of beam coincidence was ±0.7 mm in X and ±0.5 mm in Y directions (Table 2) . (Table 4) .
3.E | Translational and rotational shifts
The workflow for the dosimetric component of the daily quality assurance of a pencil beam scanning treatment unit using the Sphinx, Lynx, and PPC05 is shown. Part of the challenge with standardized guidance stems from the variability in delivery technologies (e.g., gantry, fixed-beam, etc.), techniques (e.g., double scatter, uniform scanning, etc.) as well as different IGRT imaging techniques (e.g., kV-kV, CBCT, CT-on-rails, etc.). Currently, there is an AAPM TG-224 working on a report to address these issues and provide recommendations; however, as of date, there is no official publication. There is, however, a growing consensus as to a limited set of tests and their accepted frequency from recent publications. [4] [5] [6] [7] [8] [9] Although, it is important to mention that the determination of action level tolerances still remains a challenge.
Conceptionally, in attempting to establish tolerances for specific tests of a quality assurance program, a number of strategies may be employed to determine the tolerance action value. One such approach is to follow the recommended tolerances established by published guidelines that were conceived by the consensus of a group of experienced users -that is, for example, an AAPM task group report. A second could be to evaluate the impact on the patient dose distribution due to variations in that specific parameter. For example, there have been publications characterizing the impact of spot size on treatment plan quality. 15 A third approach is to use statistical process control to evaluate whether specific parameters are behaving in a stable and controlled manner. 16, 17 With this information, it is possible to use statistical methods to determine the system specific action level tolerances due to the system performance. In using statistical process control, the methodology is to first establish a process of testing a parameter, test and observe, and characterize the behavior of the specific parameter -for example, dose output, spot size, spot position, etc. -over a time period. By characterizing the behavior, it is possible to determine when a parameter is out of control and is statistically an outlier. This helps provide guidance as to when to act. In this study, 10 months' worth of data was collected to characterize the behavior of our proton PBS delivery system. Our goal was to measure the stability of multiple parameters and establish tolerances based on our specific system performance and not on generic guidelines. With the assumption that a parameter value is approximately distributed normally, control limits based purely on the behavior of the variability can be generated. Using control
The workflow for the imaging component of the daily quality assurance of a pencil beam scanning treatment unit using the MIMI and HexaCheck is illustrated.
charts, a delivery system-specific action level (3σ) table can be determined for daily QA.
With regards to dose output, the AAPM TG 142 18 recommends the tolerance of 3% for photon and electron, whereas Lambert et al. 5 and Actis et al. 6 have used a tolerance of 2% and Younkin et al. of ±1 mm from Bizzochi et al. 7 is more stringent than ±1.5 mm suggested by Lambert et al. 5 and Younkin et al. 8 and ±2 mm applied by Actis et al. 6 Although our daily spot positions (a total of four spots couch. For our current daily QA protocol and workflow (Fig. 6 ), a tighter spot position tolerance of ±0.6 mm is feasible.
For x-ray and proton beam coincidence, we currently use a single spot of energy 106 MeV. Based on 10 months results, the deviation in coincidence was found to be within ±1.5 mm, which was used as the tolerance by Lambert et al. 5 The 3σ of beam coincidence (x ray and proton) was found to be ±0.7 mm in X and ±0.5 mm in Y directions. As shown in Fig. 6 , we use the setup field to drive the 6D T A B L E 2 Results of dose output, field homogeneity, range, width, distal-fall-off (DFO), and x-ray vs proton beam coincidence based on daily QA measurements (n = 202). 
A relative difference (Δ) was calculated by comparing daily (D) measurements against baseline (B) measurements. Upper control limit (UCL) and lower control limit (LCL) are based on statics process control (SPC) charts. UCL = +3σ and LCL = -3σ are from the average value. Specifically, the C-RAD daily QA phantom is aligned to the room isocenter using the room/gantry lasers. Once positioned, the daily QA phantom is imaged, and the agreement between the laser isocenter and surface imaging isocenter is quantified. Tolerances and stability have been previously reported by Stanley et al. 19 Our current surface imaging daily QA tests include the laser accuracy, functionality of the system, and calculation of translational shifts (tolerance ±1 mm).
Lastly, for many proton centers, efficiency is an important ele- proton beam is tested by Lambert et al. 5 only, and in-air spot size is reported by Lambert et al., 5 Actis et al., 6 and Bizzochi et al. 7 Furthermore, none of the studies [4] [5] [6] [7] [8] reported the CBCT acquisition and its functionality as a part of daily QA. This could be due to unavailability of CBCT in the treatment room or difference in daily QA policies at the authors' institutions. [4] [5] [6] [7] [8] The inclusion of CBCT in our daily QA workflow (Fig. 8) has certainly contributed about 5 min toward the total daily QA time at our center. In addition of 
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